- Coronavirus (COVID-19) and CMTThe CMTA is aware that the coronavirus (COVID-19) may have more of an impact on people and families who are at higher risk of infection, so we are reaching out to share resources and ensure you are informed.Read more ...
- CMTA Event Schedule Update from CEO Amy GrayThe CMTA has decided to postpone and/or reschedule all upcoming CMTA branch meetings, events and walks originally scheduled to occur in March through May of 2020.Read more ...
- Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth DiseaseACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.Read more ...
- Coronavirus (COVID-19) UpdateThe Centers for Disease Control and Prevention (CDC) is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China.Read more ...
- CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMTDrs. Bruce Conklin and Luke Judge will use a $653,000 grant from the CMTA to develop the gene-editing technique known as CRISPR for application to CMT2A, 2E and 2F.Read more ...